Certara (NASDAQ:CERT) Stock Price Down 3.4% – Should You Sell?

Certara, Inc. (NASDAQ:CERT) shares fell 3.4% on Tuesday . The stock traded as low as $10.60 and last traded at $10.60. 19,359 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 769,666 shares. The stock had previously closed at $10.97.

Analyst Ratings Changes

A number of analysts have weighed in on CERT shares. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, September 27th. Robert W. Baird decreased their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Finally, Barclays dropped their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $15.92.

Certara Stock Down 1.7 %

The company has a market cap of $1.89 billion, a P/E ratio of -58.80, a PEG ratio of 4.55 and a beta of 1.52. The business’s 50 day moving average price is $10.88 and its 200-day moving average price is $11.95. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same period in the prior year, the firm earned $0.06 earnings per share. Certara’s revenue was up 10.7% compared to the same quarter last year. On average, analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

A number of institutional investors and hedge funds have recently modified their holdings of CERT. Brown Brothers Harriman & Co. bought a new position in Certara during the third quarter worth about $27,292,000. Wasatch Advisors LP increased its holdings in Certara by 22.4% during the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after purchasing an additional 1,651,076 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after purchasing an additional 1,128,006 shares during the period. Daventry Group LP lifted its stake in Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after acquiring an additional 791,405 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its position in shares of Certara by 78.6% in the third quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock worth $14,123,000 after purchasing an additional 530,598 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.